

Fairview Southdale Hospital

2008

Antibiotic Susceptibility Report

Inpatient Gram Positives 2007
(all cultures sent from any inpatient areas including AM surgery, 33, ICU, 66 etc.)

Gram-Positive Organisms	Strep. pneumoniae		Group B Streptococcus		Streptococcus Viridans (Alpha)		Staph. aureus: MSSA		Staph. aureus: MRSA		Coagulase Negative Staph		Enterococcus faecalis		Enterococcus faecium	
	06	07	07	07	06	07	06	07	06	07	06	07	06	07	06	07
Year	06	07	07	07	06	07	06	07	06	07	06	07	06	07	06	07
No. Isolates	24	21	40	36	249	249	266	270	339	399	168	140	82	69		
Ampicillin		NT	100	83		NT		NT		NT	98	98	12	↓7		
Cefazolin		NT	NT	NT	100	99		0	30	33		NT		NT		
Cephalosporins-Gen 3	96	- 100*	100	95		NT		NT		NT		NT		NT		NT
Clindamycin		81	63	94	80	79	10	↓6	49	54		NT		NT		NT
Erythromycin	63	71	45	62	76	77		3	34	40		NT		NT		NT
Levofloxacin	100	100	97	NT	81	82	6	↓4	33	43	70	68**		9**		
Linezolid		NT	NT	NT	100	100	100	100	100	100	98	98	97	99		
Nitrofurantion (urine only)		NT	NT	NT		100		99		99		98		15		
Penicillin G	50	76	100	83	17	19		0	7	10	98	97		6		
Tetracycline		NT	NT	NT		98		99		85		NT		NT		
Trimeth/Sulfa (Bactrim)	58	70	NT	NT	94	99	99	100		66		NT		NT		
Vancomycin	100	100	100	100	100	100	100	100	100	100	98	↓96	37	↓29		

Numbers as expressed as % sensitive; NT = Not tested; blank = not enough isolates to report data

worse
 better
 not reported last year

*Reported as combined sensitivity to ceftriaxone & cefotaxime. Other cephalosporins will be more resistant.

** This sensitivity ONLY applies to urine culture. Do NOT use levofloxacin for other enterococcus infections.

2006

MRSA breakdown: 52% of Staph. aureus isolates are MRSA

- Hospital-acquired (FSH): 7.5% [= 20 new cases]
- Healthcare-associated: 18.5% [= 50 new cases]
- Community-acquired: 74% [= 198 new cases]

2007

MRSA breakdown: 48.7% of Staph.aureus isolates are MRSA

- New cases: 350 cases
- Healthcare Associated: 132 cases (37.7%)
- Community acquired: 218 cases (62.3%)

Inpatient Gram Negatives 2007

(all cultures sent from any inpatient areas including AM surgery, 33, ICU, 66 etc.)

Gram-Negative Bacilli	Citrobacter freundii		Enterobacter aerogenes		Enterobacter cloacae		Escherichia coli		Escherichia coli (ESBL)		Klebsiella oxytoca		Klebsiella pneumoniae		Proteus mirabilis		Pseudomonas aeruginosa		Serratia marcescens		Stenotrophomonas maltophilia		
	06	07	06	07	06	07	06	07	07	06	07	06	07	06	07	06	07	06	07	06	07	06	07
Year	06	07	06	07	06	07	06	07	07	06	07	06	07	06	07	06	07	06	07	06	07	06	07
# Isolates	16	20	16	16	41	41	363	397	9	27	33	119	116	57	52	130	98	13	18	34	11		
Ampicillin		NT		NT		NT	61	↓58	0		0		0	88	↓83		NT		NT		NT		
Ampicillin/Sulbactam (Unasyn)		5		0		0	82	↓80	25	89	↓70	97	↓94	95	↓92		NT		0		NT		
Cefazolin		NT		NT		NT	91	90	0	63	↓55	97	98	86	92		NT		NT		NT		
Ceftazidime	88	↓63	80	94 [^]	73	80 [^]	98	99	0	100	100	98	99	100	100	88	↓83	100	100 [^]	25	91		
Ceftriaxone	88	↓65	80	94 [^]	73	80 [^]	99	99	0	100	↓82	98	100	98	100		NT	100	100 [^]		NT		
Cefuroxime		67		100		12	83	86	0	100	↓80	94	94	93	97		NT				NT		
Ciprofloxacin	94	↓85	87	100	88	98	83	84	0	100	100	98	99	88	92	82	↓77	85	89	52	↓36		
Gentamicin	100	↓90	100	100	95	100	94	93	50	100	100	98	100	95	↓90	87	↓84	100	100				
Imipenem	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	93	↓91	100	100				
Levofloxacin	100	↓85	86	100	93	100	83	84	0	100	100	98	99	93	94	81	80	100	↓89				
Nitrofurantoin (urine only)		81		33		18		95	80		73		47		0		NT				NT		
Piperacillin			86	90	77	↓75	70	↓65	0		0		0	93	↓85	97	↓92	80	94	29	64		
Piperacillin/tazobactam (Zosyn)			86	100	81	83	99	↓95		100	↓67	97	97	100	100	98	↓95	80	94				
Tetracycline		NT		NT		NT		NT			NT		NT		NT		NT		NT		40		
Ticarcill/Clavulanic (Timentin)	87	↓65	79	94	63	76	93	↓90	25	100	↓73	98	97	100	100	81	↓77	85	94	37	73		
Tobramycin	100	100	100	100	95	100	94	94	50	100	100	98	100	95	92	96	98	92	↓72				
Trimeth/Sulfa (Bactrim)	94	↓80	100	100	93	98	83	↓80	75	100	100	97	98	98	↓87			100	↓94	100	100		

Numbers as expressed as % sensitive; NT = Not tested; blank = not enough isolates to report data

- worse
- better
- not reported last year

[^]Enterobacter and Serratia may develop resistance during prolonged therapy with 3rd-generation cephalosporins. Isolates that are initially susceptible may become resistant within 3-4 days.

Outpatient Gram Positive 2007

(all cultures sent from any outpatient areas including ER, 88OP etc.)

Gram-Positive Organisms	Strep. pneumoniae		Group B Streptococcus		Streptococcus Viridans (Alpha)		Staph. aureus MSSA		Staph. aureus: MRSA		Coag. Negative Staph		Enterococcus faecalis		Enterococcus faecium	
	06	07	07	07	06	07	06	07	06	07	06	07	06	07	06	07
No. Isolates	29	24	43	32	179	218	171	174	214	307	132	167	28	28		
Ampicillin		NT	100	78		NT		NT		NT		98		19		
Cephalexin		NT	NT	NT	100	↓98		0	46	↓38		NT		NT		
Cephalosporins-Gen 3		100*	100	100		NT		NT		NT		NT		NT		
Clindamycin		91	67	79	72	75	23	34	54	53		NT		NT		
Erythromycin	83	83	55	53	68	73		5	41	↓36		NT		NT		
Levofloxacin	100	100	100	NT	74	84	17	24	53	↓49	56	61**		15**		
Linezolid		NT	100	NT	100	100	100	100	100	100	94	98	100	100		
Nitrofurantoin (urine only)		NT	NT	NT		99		99		98		100		26		
Penicillin G	83	83	100	74	22	20		0		14	100	↓98	14	19		
Tetracycline	97	↓83	19	NT		95		94		81		NT		NT		
Trimeth/Sulfa (Bactrim)	86	↓75	NT	NT	97	98	100	99		76		NT		NT		
Vancomycin		100	100	100		100		100		100		98		33		

Numbers as expressed as % sensitive; NT = Not tested; blank = not enough isolates to report data

worse
 better
 not reported last year

*Reported as combined sensitivity to ceftriaxone & cefotaxime. Other cephalosporins will be more resistant.

**This sensitivity ONLY applies to urine culture. Do NOT use levofloxacin for other enterococcus infections.

Outpatient Gram Negatives 2007

(all cultures sent from any outpatient areas including ER, 88OP etc.)

Gram-Negative Bacilli	Citrobacter freundii		Enterobacter aerogenes		Enterobacter cloacae		Escherichia coli		Escherichia coli (ESBL) *		Klebsiella oxytoca		Klebsiella pneumoniae		Klebsiella pneumoniae (ESBL)		Proteus mirabilis		Pseudomonas aeruginosa		Serratia marcescens		Stenotrophomonas maltophilia	
	Year	06	07	06	07	06	07	06	07	07	06	07	06	07	07	06	07	06	07	06	07	06	07	07
No. Isolates	26	27	18	14	31	45	641	766	10	24	29	150	154	3	62	74	128	126	18	12	13			
Amoxicillin		NT				0	63	63	0		0		0	0	84	92		NT		NT	NT			
Amoxicillin/Clavulanic (Augmentin)		15				0	87	83		96	↓93	96	97		92	96		NT		0	NT			
Ceftazidime		23		93		80		99	0		100		99	0		99		91		100	75			
Cephalexin		NT		NT		NT	93	91	0	75	↓66	97	99	0	89	95		NT		NT	NT			
Ceftriaxone	100 [^]	↓85 [^]	83 [^]	93 [^]	81 [^]	80 [^]	98	99	13	100	100	98	99	0	95	99		NT	94 [^]	100 [^]	NT			
Ciprofloxacin	96	↓93	100	100	94	100	86	86	13	100	↓93	95	97	0	84	91	76	82	94	↓83	42			
Gentamicin		96		100		100		96	50		100		99	67		96		88		83	NT			
Imipenem		□							100					100		□		93		□	NT			
Levofloxacin	100	↓96	100	100	93	100	86	87	13	100	↓97	95	97	0	92	95	80	83	94	↓92	NT			
Nitrofurantoin (urine only)	94	↓75		0		13	97	95	83	79	↓68		28	0		0		NT		0	NT			
Pipercillin		□						67			0							99			27			
Pipercillin/Tazobactam (Zosyn)		□				100		98			90							100						
Tetracycline	94	↓75	100	100	90	↓78	81	79	50	93	↓84	92	91	67		0		NT		63	36			
Ticarcillin/Clavulanic (Timentin)		84		85		82		90	38		97		99	0		100		88		100	75			
Tobramycin		96		100		96		96	38		100		99	67		97		98		100	NT			
Trimeth/Sulfa (Bactrim)	88	↓81	100	100	90	96	83	82	75	100	↓93	91	92	0	94	↓88			100	100	100			

Numbers as expressed as % sensitive; NT = Not tested; blank = not enough isolates to report data

- worse
- better
- not reported last year

[^]Enterobacter and Serratia may develop resistance during prolonged therapy with 3rd-generation cephalosporins.

Isolates that are initially susceptible may become resistant within 3-4 days.

*Escherichia Coli (ESBL) are all from urine culture

Compiled by Helen Peng and Gaye Unger

Approved by Infection Prevention Committee 4/08